<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024943</url>
  </required_header>
  <id_info>
    <org_study_id>Attain Stability Quad PAS</org_study_id>
    <nct_id>NCT04024943</nct_id>
  </id_info>
  <brief_title>Personalized CRT - Attain Stability Quad Post-Approval Study</brief_title>
  <acronym>ASQ</acronym>
  <official_title>Personalized CRT - Attain Stability Quad Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Post-Approval Study (PAS) is to evaluate the long-term performance of the
      Model 4798 Left Ventricular (LV) lead in a real-world patient population. Patients will be
      followed for the duration of the PAS. This study is required by FDA as a condition of
      approval of the Model 4798 LV lead and is integrated within the Product Surveillance Registry
      (PSR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Attain Stability Quad (ASQ) PAS is a multi-center, single arm, prospective observational
      study. However, in the US, retrospective enrollments from participants in the IDE study (IDE
      #G170020) are allowed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Percentage of patients without a lead- related event at 5 years post-implant</measure>
    <time_frame>5 years</time_frame>
    <description>To demonstrate that the complication-free probability is greater than 92.5% at five years post-implant for Attain Stability Quad LV leads.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lead-related adverse device effects</measure>
    <time_frame>5 years</time_frame>
    <description>The secondary objectives are descriptive in nature and are intended to gain additional information about the safety and performance of the Product:
• To summarize all Attain Stability Quad lead-related ADEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of explanted leads that have been returned</measure>
    <time_frame>5 years</time_frame>
    <description>The secondary objectives are descriptive in nature and are intended to gain additional information about the safety and performance of the Product:
• To summarize analysis results from explanted and returned Attain Stability Quad leads</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quadripolar LV Lead</intervention_name>
    <description>The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.</description>
    <other_name>Medtronic CRT-P</other_name>
    <other_name>Medtronic CRT-D</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients that are or will be implanted with a Model 4798 lead
        and a Medtronic CRT device.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient or legally authorized representative provides written authorization and/or
             consent per institution and geographical requirements

          -  Patient has or is intended to receive or be treated with a Model 4798 lead and a
             Medtronic CRT device

          -  Patient within 30 days of therapy received at the time of their initial PSR platform
             enrollment

        Exclusion Criteria:

          -  Patient who is, or is expected to be inaccessible for follow-up

          -  Patient with exclusion criteria required by local law

          -  Patient is currently enrolled in or plans to enroll in any concurrent drug and/or
             device study that may confound results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital - Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Aurora Cardiovascular Services</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>CHRU La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Milhem</last_name>
      <phone>+33 546456644</phone>
      <email>antoine.milhem@ch-larochelle.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz-Hospital Koln</name>
      <address>
        <city>Köln</city>
        <zip>50733</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Winter</last_name>
      <phone>+49 (0)221 7712-351</phone>
      <email>inneremedkardio.kh-vinzenz@cellitinnen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universitat Tubingen - Universitatsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Müller</last_name>
      <phone>+4970712980642</phone>
      <email>k.mueller@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Lunati</last_name>
      <phone>+39 264442611</phone>
      <email>maurizio.lunati@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Jung Park</last_name>
      <phone>+82 234102578</phone>
      <email>orthovics@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara - National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azlan Hussin</last_name>
      <phone>+60 326178200</phone>
      <email>azlan@ijn.com.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario da Coruna</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Pérez Álvarez</last_name>
      <phone>+34 981 178 000</phone>
      <email>luisa.perez.alvarez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Martínez Sande</last_name>
      <phone>+34 981950000</phone>
      <email>luismartinezsande@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karnsjukhuset Skovde</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Henrik Falmer-Hansen</last_name>
      <phone>+46 500431000</phone>
      <email>hans_henrik.falmer@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Archana Rao</last_name>
      <phone>+44 1516001457</phone>
      <email>archana.rao@lhch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS - Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Zaidi</last_name>
      <phone>+44 1619011731</phone>
      <email>amir.zaidi@cmft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital - South Tees Hospitals NHS</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas John Linker</last_name>
      <phone>+44 1642282412</phone>
      <email>nick.linker@stees.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

